This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 6, 2011 /PRNewswire/ -- Victor Grifols Roura, president and managing director of Grifols, has been selected as the "Business Leader of the Year 2011" by the Spain – U.S. Chamber of Commerce, the premier forum fostering commercial, economic and industrial relations between
the United States. This award, given annually, recognizes the professional career of business leaders who stand out in their industries, as well as their contribution to the globalization of the economy. In the case of Victor Grifols, his leadership as sales manager of Grifols since 1979, and as president and managing director since 1987 has driven the transition of Grifols and allowed it to grow from a family company to the third largest producer of plasma protein therapies worldwide.
The award will be presented by
Angeles Gonzalez Sinde, Minister of Cultural Affairs of the Government of
Spain during the gala dinner that will take place on
December 6th, 2011 at the Hotel Pierre in
New York, and attendees will include notable political and business figures from both
the United States.
Victor Grifols Roura studied Business Science at the
University of Barcelona and joined Grifols in 1973. A man of great strategic and commercial vision, as the Commercial Director he was the architect of the restoration of Grifols' sales network in
Spain. Additionally, as managing director, he was responsible for the in-depth reorganization of the company that allowed it to establish the basis for the multinational group that Grifols is today.
For Victor Grifols, international expansion has always been and continues to be essential to ensure the growth of his organization. In 1988 he opened the company's first international subsidiary in
Portugal, inaugurating the process of progressive expansion of Grifols in other markets, whose first objective was
Latin America, though entrance into
the United States market was always the long-term goal.
During the 1990's the international expansion of the group took off, and one of the decisive factors of this was the acquiring of two Food & Drug Administration licenses in 1995: the
Establishment License for the production plant in Parets del Valles (
Barcelona, Spain), and the
Product License for its product, Albumin.
Miami was designated as the site for the first American subsidiary of Grifols, with
Central America and the
Caribbean as its principal areas of influence, followed by
Chile in 1991. The disappearance of the Soviet Bloc in 1992 created the opportunity for a new subsidiary in the
Czech Republic, and the following year,
Mexico was chosen as the next country for expansion.
In 1997, European expansion began through acquisitions. The purchase of subsidiaries of Alpha Therapeutic Corporation in the
Italy permitted a rapid penetration into those markets and generated enough confidence for the company to leap to
the United States, a world leader in the blood derivatives sector. In the years 2002 and 2003, two acquisitions planted the roots of Grifols in the US: the purchase of SeraCare, that ensured the supply of raw materials through the expansion of its plasma acquisition centers, and a large part of the assets of Alpha Therapeutic Corporation, including its plasma division and protein purification plants for the in
Presently, Grifols maintains a strong presence on the North American market and the internationalization of the group has translated into a global commercial presence including more than 90 countries with direct subsidiaries in 24.